“Usona’s roundtable on preparing for delivery of care provided a meaningful forum to consider what it will take to deliver psychedelic care responsibly within large healthcare systems like the VA. Usona’s collaboration through the Phase 3 trial at our Portland VA site and its support for our investigator-initiated studies, including a completed study of psilocybin group therapy and an ongoing study piloting psilocybin therapy for Veterans with stimulant use disorder within a VA residential treatment program, has also played a pivotal role in advancing this work. The roundtable discussions on group-based care, interdisciplinary teams, and the integration of peer support directly reflected the clinical questions we face at the Portland VA and OHSU as we work to develop models that are safe, scalable, and responsive to the needs of patients and their families. The event also highlighted a growing alignment across the field: team-based approaches grounded in real-world clinical realities will be essential for equitable access. Participating in the conversation underscored how much progress is possible when researchers, clinicians, and sponsors work collaboratively to translate emerging evidence into models of care that inform best practices across real-world clinical settings.”